Noradrenergic dysfunction contributes to cognitive impairment in Alzheimer's Disease (AD)
and Parkinson's Disease (PD). Conventional therapeutic strategies seek to enhance …

The brain noradrenergic system supplies the neurotransmitter norepinephrine throughout
the brain via widespread efferent projections, and plays a pivotal role in modulating …

Many aspects of cognition and behaviour are regulated by noradrenergic projections to the
forebrain originating from the locus coeruleus, acting through alpha and beta …

Pathological alterations to the locus coeruleus, the major source of noradrenaline in the
brain, are histologically evident in early stages of neurodegenerative diseases. Novel MRI …

The locus coeruleus-noradrenergic (LC-NA) system supplies the cerebral cortex with
norepinephrine, a key modulator of cognition. Neurodegeneration of the LC is an early …

There is clear, early noradrenergic dysfunction in Alzheimer's disease. This is likely
secondary to pathological tau deposition in the locus coeruleus, the pontine nucleus that …

In the past, manipulation of the cholinergic system was seen as the most likely therapeutic
for neurodegeneration-based cognitive decline in Alzheimer's disease (AD)(Whitehouse et …

The locus coeruleus (LC) is a small brainstem structure located in the lower pons and is the
main source of noradrenaline (NA) in the brain. Via its phasic and tonic firing, it modulates …

It has been known for decades that degeneration of the locus coeruleus (LC), the major
noradrenergic nucleus in the brain, occurs in both Alzheimer's disease (AD) and Parkinson's …

Locus coeruleus (LC) neurons in the brainstem send extensive noradrenergic (NE)-ergic
terminals to the majority of brain regions, particularly those involved in cognitive function …